Hepatocellular Carcinoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Hepatocellular Carcinoma – Pipeline Review, H2 2017’, provides an overview of the Hepatocellular Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma

The report reviews pipeline therapeutics for Hepatocellular Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hepatocellular Carcinoma therapeutics and enlists all their major and minor projects

The report assesses Hepatocellular Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Abivax SA

ACEA Biosciences Inc

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

Amgen Inc

AndroScience Corp

ArQule Inc

Array BioPharma Inc

Aslan Pharmaceuticals Pte Ltd

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Bio-Cancer Treatment International Ltd

Biomics Biotechnologies Co Ltd

Bioneer Corp

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Can-Fite BioPharma Ltd

CASI Pharmaceuticals Inc

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Cellivery Therapeutics Inc

Celsion Corp

China Medical System Holdings Ltd

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co Ltd

Conatus Pharmaceuticals Inc

Curevac AG

Delcath Systems Inc

Double Bond Pharmaceutical International AB

eFFECTOR Therapeutics Inc

Eiger BioPharmaceuticals Inc

Eisai Co Ltd

Eli Lilly and Co

Epeius Biotechnologies Corp

Epizyme Inc

eTheRNA Immunotherapies NV

Eureka Therapeutics Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Galaxy Biotech LLC

Genelux Corp

Genentech Inc

Genoscience Pharma

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Golden Biotechnology Corp

Green Cross Cell Corp

Green Cross Corp

H3 Biomedicine Inc

Horizon Pharma Plc

Immatics Biotechnologies GmbH

Immunicum AB

Immunitor Inc

Immunomedics Inc

Immunovative Therapies Ltd

In-Cell-Art SAS

Incyte Corp

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

InteRNA Technologies BV

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

KAHR medical Ltd

Karcinolys SAS

Kite Pharma Inc

Komipharm International Co Ltd

Kowa Co Ltd

Ligand Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

MaxCyte Inc

MedImmune LLC

Medivir AB

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

Mina Therapeutics Ltd

Molecular Templates Inc

MTG Biotherapeutics Inc

MultiCell Technologies Inc

NeuroVive Pharmaceutical AB

NormOxys Inc

Novartis AG

NovaTarg Therapeutics Inc

Nymox Pharmaceutical Corp

Omeros Corp

Oncolys BioPharma Inc

Oneness Biotech Co Ltd

Ono Pharmaceutical Co Ltd

OSE Immunotherapeutics

Panacea Pharmaceuticals Inc

PepVax Inc

Peregrine Pharmaceuticals Inc

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

PharmaEssentia Corp

Provecs Medical GmbH (Inactive)

Provectus Biopharmaceuticals Inc

Q BioMed Inc

RedHill Biopharma Ltd

Regulus Therapeutics Inc

Samumed LLC

Saronic Biotechnology Inc

Shenogen Pharma Group Ltd

Sillajen Biotherapeutics

Simcere Pharmaceutical Group

Sun Pharma Advanced Research Company Ltd

Taiwan Liposome Company Ltd

Takeda Pharmaceutical Co Ltd

TC BioPharm Ltd

tella Inc

Tessa Therapeutics Pte Ltd

Therapure Biopharma Inc

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

Tumorend LLC

Twoxar Inc

UbiVac LLC

VasGene Therapeutics Inc

Vaxon Biotech

Verlyx Pharma Inc

VG Life Sciences Inc

Vicus Therapeutics LLC

Xspray Pharma AB

Yooyoung Pharm Co Ltd

Zhejiang Conba Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Hepatocellular Carcinoma - Overview 9

Hepatocellular Carcinoma - Therapeutics Development 10

Hepatocellular Carcinoma - Therapeutics Assessment 42

Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 64

Hepatocellular Carcinoma - Drug Profiles 125

Hepatocellular Carcinoma - Dormant Projects 1068

Hepatocellular Carcinoma - Discontinued Products 1076

Hepatocellular Carcinoma - Product Development Milestones 1079

Appendix 1092

List of Tables

List of Tables

Number of Products under Development for Hepatocellular Carcinoma, H2 2017 37

Number of Products under Development by Companies, H2 2017 39

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 40

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 41

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 42

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 43

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 44

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 45

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 46

Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 47

Number of Products under Development by Universities/Institutes, H2 2017 48

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 50

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 51

Products under Development by Companies, H2 2017 52

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 53

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 54

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 55

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 56

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 57

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 58

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 59

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 60

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 61

Products under Development by Companies, H2 2017 (Contd..10), H2 2017 62

Products under Development by Companies, H2 2017 (Contd..11), H2 2017 63

Products under Development by Companies, H2 2017 (Contd..12), H2 2017 64

Products under Development by Companies, H2 2017 (Contd..13), H2 2017 65

Products under Development by Universities/Institutes, H2 2017 66

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 67

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 68

Number of Products by Stage and Target, H2 2017 70

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 71

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 72

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 73

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 74

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 75

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 76

Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 77

Number of Products by Stage and Mechanism of Action, H2 2017 79

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 80

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 81

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 82

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 83

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 84

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 85

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 86

Number of Products by Stage and Route of Administration, H2 2017 88

Number of Products by Stage and Molecule Type, H2 2017 90

Hepatocellular Carcinoma – Pipeline by AbbVie Inc, H2 2017 91

Hepatocellular Carcinoma – Pipeline by Abivax SA, H2 2017 91

Hepatocellular Carcinoma – Pipeline by ACEA Biosciences Inc, H2 2017 92

Hepatocellular Carcinoma – Pipeline by Adaptimmune Therapeutics Plc, H2 2017 92

Hepatocellular Carcinoma – Pipeline by Advenchen Laboratories LLC, H2 2017 93

Hepatocellular Carcinoma – Pipeline by Amgen Inc, H2 2017 93

Hepatocellular Carcinoma – Pipeline by AndroScience Corp, H2 2017 94

Hepatocellular Carcinoma – Pipeline by ArQule Inc, H2 2017 94

Hepatocellular Carcinoma – Pipeline by Array BioPharma Inc, H2 2017 94

Hepatocellular Carcinoma – Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 95

Hepatocellular Carcinoma – Pipeline by AstraZeneca Plc, H2 2017 95

Hepatocellular Carcinoma – Pipeline by AVEO Pharmaceuticals Inc, H2 2017 96

Hepatocellular Carcinoma – Pipeline by Bayer AG, H2 2017 96

Hepatocellular Carcinoma – Pipeline by BeiGene Ltd, H2 2017 97

Hepatocellular Carcinoma – Pipeline by Bio-Cancer Treatment International Ltd, H2 2017 97

Hepatocellular Carcinoma – Pipeline by Biomics Biotechnologies Co Ltd, H2 2017 98

Hepatocellular Carcinoma – Pipeline by Bioneer Corp, H2 2017 98

Hepatocellular Carcinoma – Pipeline by Blueprint Medicines Corp, H2 2017 99

Hepatocellular Carcinoma – Pipeline by Boehringer Ingelheim GmbH, H2 2017 99

Hepatocellular Carcinoma – Pipeline by Boston Biomedical Inc, H2 2017 99

Hepatocellular Carcinoma – Pipeline by Bristol-Myers Squibb Co, H2 2017 100

Hepatocellular Carcinoma – Pipeline by Can-Fite BioPharma Ltd, H2 2017 101

Hepatocellular Carcinoma – Pipeline by CASI Pharmaceuticals Inc, H2 2017 101

Hepatocellular Carcinoma – Pipeline by CBT Pharmaceuticals Inc, H2 2017 101

Hepatocellular Carcinoma – Pipeline by CCRP Therapeutics GmbH, H2 2017 102

Hepatocellular Carcinoma – Pipeline by Celgene Corp, H2 2017 102

Hepatocellular Carcinoma – Pipeline by Celldex Therapeutics Inc, H2 2017 103

Hepatocellular Carcinoma – Pipeline by Cellivery Therapeutics Inc, H2 2017 103

Hepatocellular Carcinoma – Pipeline by Celsion Corp, H2 2017 104

Hepatocellular Carcinoma – Pipeline by China Medical System Holdings Ltd, H2 2017 104

Hepatocellular Carcinoma – Pipeline by Chipscreen Biosciences Ltd, H2 2017 104

Hepatocellular Carcinoma – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 105

Hepatocellular Carcinoma – Pipeline by Conatus Pharmaceuticals Inc, H2 2017 105

Hepatocellular Carcinoma – Pipeline by Curevac AG, H2 2017 106

Hepatocellular Carcinoma – Pipeline by Delcath Systems Inc, H2 2017 106

Hepatocellular Carcinoma – Pipeline by Double Bond Pharmaceutical International AB, H2 2017 107

Hepatocellular Carcinoma – Pipeline by eFFECTOR Therapeutics Inc, H2 2017 107

Hepatocellular Carcinoma – Pipeline by Eiger BioPharmaceuticals Inc, H2 2017 107

Hepatocellular Carcinoma – Pipeline by Eisai Co Ltd, H2 2017 108

Hepatocellular Carcinoma – Pipeline by Eli Lilly and Co, H2 2017 109

Hepatocellular Carcinoma – Pipeline by Epeius Biotechnologies Corp, H2 2017 109

Hepatocellular Carcinoma – Pipeline by Epizyme Inc, H2 2017 110

Hepatocellular Carcinoma – Pipeline by eTheRNA Immunotherapies NV, H2 2017 110

Hepatocellular Carcinoma – Pipeline by Eureka Therapeutics Inc, H2 2017 110

Hepatocellular Carcinoma – Pipeline by Exelixis Inc, H2 2017 111

Hepatocellular Carcinoma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 111

Hepatocellular Carcinoma – Pipeline by Faron Pharmaceuticals Oy, H2 2017 112

Hepatocellular Carcinoma – Pipeline by Galaxy Biotech LLC, H2 2017 112

Hepatocellular Carcinoma – Pipeline by Genelux Corp, H2 2017 112

Hepatocellular Carcinoma – Pipeline by Genentech Inc, H2 2017 113

Hepatocellular Carcinoma – Pipeline by Genoscience Pharma, H2 2017 113

Hepatocellular Carcinoma – Pipeline by Genosco Inc, H2 2017 114

Hepatocellular Carcinoma – Pipeline by Gilead Sciences Inc, H2 2017 114

Hepatocellular Carcinoma – Pipeline by GlaxoSmithKline Plc, H2 2017 115

Hepatocellular Carcinoma – Pipeline by Golden Biotechnology Corp, H2 2017 115

Hepatocellular Carcinoma – Pipeline by Green Cross Cell Corp, H2 2017 116

Hepatocellular Carcinoma – Pipeline by Green Cross Corp, H2 2017 116

Hepatocellular Carcinoma – Pipeline by H3 Biomedicine Inc, H2 2017 117

Hepatocellular Carcinoma – Pipeline by Horizon Pharma Plc, H2 2017 117

Hepatocellular Carcinoma – Pipeline by Immatics Biotechnologies GmbH, H2 2017 117

Hepatocellular Carcinoma – Pipeline by Immunicum AB, H2 2017 118

Hepatocellular Carcinoma – Pipeline by Immunitor Inc, H2 2017 118

Hepatocellular Carcinoma – Pipeline by Immunomedics Inc, H2 2017 119

Hepatocellular Carcinoma – Pipeline by Immunovative Therapies Ltd, H2 2017 119

Hepatocellular Carcinoma – Pipeline by In-Cell-Art SAS, H2 2017 119

Hepatocellular Carcinoma – Pipeline by Incyte Corp, H2 2017 120

Hepatocellular Carcinoma – Pipeline by Inovio Pharmaceuticals Inc, H2 2017 120

Hepatocellular Carcinoma – Pipeline by Inspyr Therapeutics Inc, H2 2017 121

Hepatocellular Carcinoma – Pipeline by InteRNA Technologies BV, H2 2017 121

Hepatocellular Carcinoma – Pipeline by Ipsen SA, H2 2017 122

Hepatocellular Carcinoma – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 122

Hepatocellular Carcinoma – Pipeline by Johnson & Johnson, H2 2017 123

Hepatocellular Carcinoma – Pipeline by KAHR medical Ltd, H2 2017 123

Hepatocellular Carcinoma – Pipeline by Karcinolys SAS, H2 2017 123

Hepatocellular Carcinoma – Pipeline by Kite Pharma Inc, H2 2017 124

Hepatocellular Carcinoma – Pipeline by Komipharm International Co Ltd, H2 2017 124

Hepatocellular Carcinoma – Pipeline by Kowa Co Ltd, H2 2017 125

Hepatocellular Carcinoma – Pipeline by Ligand Pharmaceuticals Inc, H2 2017 125

Hepatocellular Carcinoma – Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 126

Hepatocellular Carcinoma – Pipeline by MaxCyte Inc, H2 2017 126

Hepatocellular Carcinoma – Pipeline by MedImmune LLC, H2 2017 127

Hepatocellular Carcinoma – Pipeline by Medivir AB, H2 2017 127

Hepatocellular Carcinoma – Pipeline by Merck & Co Inc, H2 2017 128

Hepatocellular Carcinoma – Pipeline by Merck KGaA, H2 2017 128

Hepatocellular Carcinoma – Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 129

Hepatocellular Carcinoma – Pipeline by Midatech Pharma Plc, H2 2017 129

Hepatocellular Carcinoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 129

Hepatocellular Carcinoma – Pipeline by Mina Therapeutics Ltd, H2 2017 130

Hepatocellular Carcinoma – Pipeline by Molecular Templates Inc, H2 2017 130

Hepatocellular Carcinoma – Pipeline by MTG Biotherapeutics Inc, H2 2017 130

Hepatocellular Carcinoma – Pipeline by MultiCell Technologies Inc, H2 2017 131

Hepatocellular Carcinoma – Pipeline by NeuroVive Pharmaceutical AB, H2 2017 131

Hepatocellular Carcinoma – Pipeline by NormOxys Inc, H2 2017 132

Hepatocellular Carcinoma – Pipeline by Novartis AG, H2 2017 132

Hepatocellular Carcinoma – Pipeline by NovaTarg Therapeutics Inc, H2 2017 133

Hepatocellular Carcinoma – Pipeline by Nymox Pharmaceutical Corp, H2 2017 133

Hepatocellular Carcinoma – Pipeline by Omeros Corp, H2 2017 134

Hepatocellular Carcinoma – Pipeline by Oncolys BioPharma Inc, H2 2017 134

Hepatocellular Carcinoma – Pipeline by Oneness Biotech Co Ltd, H2 2017 135

Hepatocellular Carcinoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 135

Hepatocellular Carcinoma – Pipeline by OSE Immunotherapeutics, H2 2017 136

Hepatocellular Carcinoma – Pipeline by Panacea Pharmaceuticals Inc, H2 2017 136

Hepatocellular Carcinoma – Pipeline by PepVax Inc, H2 2017 136

Hepatocellular Carcinoma – Pipeline by Peregrine Pharmaceuticals Inc, H2 2017 137

Hepatocellular Carcinoma – Pipeline by Pfizer Inc, H2 2017 138

Hepatocellular Carcinoma – Pipeline by Pharma Mar SA, H2 2017 138

Hepatocellular Carcinoma – Pipeline by PharmAbcine Inc, H2 2017 139

Hepatocellular Carcinoma – Pipeline by PharmaEssentia Corp, H2 2017 139

Hepatocellular Carcinoma – Pipeline by Provecs Medical GmbH (Inactive), H2 2017 139

Hepatocellular Carcinoma – Pipeline by Provectus Biopharmaceuticals Inc, H2 2017 140

Hepatocellular Carcinoma – Pipeline by Q BioMed Inc, H2 2017 140

Hepatocellular Carcinoma – Pipeline by RedHill Biopharma Ltd, H2 2017 141

Hepatocellular Carcinoma – Pipeline by Regulus Therapeutics Inc, H2 2017 141

Hepatocellular Carcinoma – Pipeline by Samumed LLC, H2 2017 141

Hepatocellular Carcinoma – Pipeline by Saronic Biotechnology Inc, H2 2017 142

Hepatocellular Carcinoma – Pipeline by Shenogen Pharma Group Ltd, H2 2017 142

Hepatocellular Carcinoma – Pipeline by Sillajen Biotherapeutics, H2 2017 143

Hepatocellular Carcinoma – Pipeline by Simcere Pharmaceutical Group, H2 2017 143

Hepatocellular Carcinoma – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 144

Hepatocellular Carcinoma – Pipeline by Taiwan Liposome Company Ltd, H2 2017 144

Hepatocellular Carcinoma – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 145

Hepatocellular Carcinoma – Pipeline by TC BioPharm Ltd, H2 2017 145

Hepatocellular Carcinoma – Pipeline by tella Inc, H2 2017 145

Hepatocellular Carcinoma – Pipeline by Tessa Therapeutics Pte Ltd, H2 2017 146

Hepatocellular Carcinoma – Pipeline by Therapure Biopharma Inc, H2 2017 146

Hepatocellular Carcinoma – Pipeline by Tiziana Life Sciences Plc, H2 2017 146

Hepatocellular Carcinoma – Pipeline by TRACON Pharmaceuticals Inc, H2 2017 147

Hepatocellular Carcinoma – Pipeline by Tumorend LLC, H2 2017 147

Hepatocellular Carcinoma – Pipeline by Twoxar Inc, H2 2017 148

Hepatocellular Carcinoma – Pipeline by UbiVac LLC, H2 2017 148

Hepatocellular Carcinoma – Pipeline by VasGene Therapeutics Inc, H2 2017 148

Hepatocellular Carcinoma – Pipeline by Vaxon Biotech, H2 2017 149

Hepatocellular Carcinoma – Pipeline by Verlyx Pharma Inc, H2 2017 149

Hepatocellular Carcinoma – Pipeline by VG Life Sciences Inc, H2 2017 149

Hepatocellular Carcinoma – Pipeline by Vicus Therapeutics LLC, H2 2017 150

Hepatocellular Carcinoma – Pipeline by Xspray Pharma AB, H2 2017 150

Hepatocellular Carcinoma – Pipeline by Yooyoung Pharm Co Ltd, H2 2017 150

Hepatocellular Carcinoma – Pipeline by Zhejiang Conba Pharmaceutical Co Ltd, H2 2017 151

Hepatocellular Carcinoma – Dormant Projects, H2 2017 1095

Hepatocellular Carcinoma – Dormant Projects, H2 2017 (Contd..1), H2 2017 1096

Hepatocellular Carcinoma – Dormant Projects, H2 2017 (Contd..2), H2 2017 1097

Hepatocellular Carcinoma – Dormant Projects, H2 2017 (Contd..3), H2 2017 1098

Hepatocellular Carcinoma – Dormant Projects, H2 2017 (Contd..4), H2 2017 1099

Hepatocellular Carcinoma – Dormant Projects, H2 2017 (Contd..5), H2 2017 1100

Hepatocellular Carcinoma – Dormant Projects, H2 2017 (Contd..6), H2 2017 1101

Hepatocellular Carcinoma – Dormant Projects, H2 2017 (Contd..7), H2 2017 1102

Hepatocellular Carcinoma – Discontinued Products, H2 2017 1103

Hepatocellular Carcinoma – Discontinued Products, H2 2017 (Contd..1), H2 2017 1104

Hepatocellular Carcinoma – Discontinued Products, H2 2017 (Contd..2), H2 2017 1105

List of Figures

List of Figures

Number of Products under Development for Hepatocellular Carcinoma, H2 2017 37

Number of Products under Development by Companies, H2 2017 38

Number of Products under Development by Universities/Institutes, H2 2017 48

Number of Products by Top 10 Targets, H2 2017 69

Number of Products by Stage and Top 10 Targets, H2 2017 69

Number of Products by Top 10 Mechanism of Actions, H2 2017 78

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 78

Number of Products by Top 10 Routes of Administration, H2 2017 87

Number of Products by Stage and Top 10 Routes of Administration, H2 2017 87

Number of Products by Top 10 Molecule Types, H2 2017 89

Number of Products by Stage and Top 10 Molecule Types, H2 2017 89

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports